Results 161 to 170 of about 53,199 (230)

Bortezomib in Patients Who Fail BTKi in Waldenström Macroglobulinaemia. [PDF]

Hematol Rep
Khwaja J, Japzon N, Gatto S, Lindsay J, Kyriakou C, D'Sa S.   +5 more
europepmc   +1 more source

Bortezomib synergizes with homoharringtonine in FLT3-ITD-relapsed/refractory acute myeloid leukemia by inducing FLT3-ITD protein degradation. [PDF]

Clin Exp Med
Wei M, Wang F, Huang D, Kang Z, Yang Y, Zhang C, Lou J, Yan J.   +7 more
europepmc   +1 more source

Treatment of antibody-mediated rejection in heart transplantation: from empirical combination to multi-target precision intervention. [PDF]

Front Immunol
Xu N, Dong Y, Yue Y, Zhou L.
europepmc   +1 more source

Maintenance therapy and improved relapse-free survival in patients with monoclonal gammopathy of renal significance. [PDF]

Blood Adv
Cottini F, Iyer S, Avila-Rodriguez A, Sweiss K, Uzoka C, Chen Z, Ma W, Umyarova E, Thakur A, Satoskar A, Rodriguez P, Sanchez M.   +11 more
europepmc   +1 more source

Neuralgic Amyotrophy Following B-Cell Maturation Antigen-Directed CAR-T Therapy. [PDF]

Muscle Nerve
Pérez-Torres EJ, Madeeva DV, Cohen AD, Garfall AL, Karam C.   +4 more
europepmc   +1 more source

Ferroptosis in multiple myeloma: molecular mechanisms and therapeutic opportunities. [PDF]

Front Oncol
Jiang W, Xu L, Zhu C, Bai G, Peng S, Ma N.   +5 more
europepmc   +1 more source

<i>Erratum</i> to: "Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trial". [PDF]

Haematologica
Manier S, Dimopoulos MA, Leleu XP, Moreau P, Cavo M, Goldschmidt H, Orlowski RZ, Tron M, Tekle C, Brégeault MF, Shafer AT, Beksac M, Facon T.   +12 more
europepmc   +1 more source

Efficacy and safety of daratumumab-based quadruplet therapy vs non-daratumumab-based triplet therapy in newly diagnosed multiple myeloma patients: A GRADE assessed systematic review and meta-analysis of randomized controlled trials. [PDF]

Ther Adv Hematol
Osama M, Khan MH, Tahir A, Hussain A, Iftikhar A, Ali A, Khan S, Bilal Hassan M, Alam I, Khan Z, Afridi A, Ebad Ur Rehman M, Gul A, Thada PK.   +13 more
europepmc   +1 more source

Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) induction prior to autologous haematopoietic stem cell transplant/transplantation in newly diagnosed multiple myeloma. [PDF]

Br J Haematol
Marcoux C, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Ahmed S, Deeba RE, Tang G, Aljawai Y, Lee HC, Patel KK, Gaballa MR, Kebriaei P, Thomas SK, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH, Pasvolsky O.   +22 more
europepmc   +1 more source

Isatuximab: A Review in Transplant-Ineligible Newly Diagnosed Multiple Myeloma. [PDF]

Target Oncol
Hoy SM.
europepmc   +1 more source